Gargoyle Investment Advisor’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gargoyle Investment Advisor’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-38,559	Closed	-$570K	–	203
2017 Q1	$570K	Hold	38,559	–	–	0.22%	117
2016 Q4	$624K	Hold	38,559	–	–	0.24%	110
2016 Q3	$699K	Hold	38,559	–	–	0.26%	117
2016 Q2	$636K	Buy	+38,559	New	+$624K	0.24%	126

Other funds holding HZNP

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Gargoyle Investment Advisor's HZNP Position: Q2 2017 in Review

Gargoyle Investment Advisor sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 38,559 shares — an estimated $570K sold.

Gargoyle Investment Advisor first reported a position in HZNP in Q2 2016 and held it in 4 quarters. The position peaked at $699K in Q3 2016. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

Gargoyle Investment Advisor reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Gargoyle Investment Advisor sold 38,559 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $570K.
Gargoyle Investment Advisor first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 4 quarters.
Gargoyle Investment Advisor's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $699K in Q3 2016.
190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Gargoyle Investment Advisor's 13F filing for Q2 2017, filed 2 Aug 2017.